{"organizations": [], "uuid": "4af92a737543cc42d7868e3098251e0e3d7b5d47", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-baxter-announces-us-fda-approval-o/brief-baxter-announces-u-s-fda-approval-of-ready-to-use-bivalirudin-idUSASB0C1OY", "country": "US", "domain_rank": 408, "title": "BRIEF-Baxter Announces U.S. FDA Approval Of Ready-To-Use Bivalirudin", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T15:42:00.000+02:00", "replies_count": 0, "uuid": "4af92a737543cc42d7868e3098251e0e3d7b5d47"}, "author": "", "url": "https://www.reuters.com/article/brief-baxter-announces-us-fda-approval-o/brief-baxter-announces-u-s-fda-approval-of-ready-to-use-bivalirudin-idUSASB0C1OY", "ord_in_thread": 0, "title": "BRIEF-Baxter Announces U.S. FDA Approval Of Ready-To-Use Bivalirudin", "locations": [], "entities": {"persons": [{"name": "ready-to-use bivalirudin", "sentiment": "negative"}, {"name": "bivalirudin", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "baxter international inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 45 PM / Updated 11 minutes ago BRIEF-Baxter Announces U.S. FDA Approval Of Ready-To-Use Bivalirudin Reuters Staff \nJan 22 (Reuters) - Baxter International Inc: \n* BAXTER ANNOUNCES U.S. FDA APPROVAL OF READY-TO-USE CARDIOVASCULAR MEDICATION BIVALIRUDIN \n* BAXTER INTERNATIONAL SAYS U.S. FDA APPROVED BIVALIRUDIN IN 0.9 PERCENT SODIUM CHLORIDE INJECTION \n* BAXTER INTERNATIONAL INC - BIVALIRUDIN IS EXPECTED TO LAUNCH IN UNITED STATES IN EARLY 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-22T15:42:00.000+02:00", "crawled": "2018-01-22T16:02:38.015+02:00", "highlightTitle": ""}